Sinopharm Group (1099.HK) rebounds after posting an upbeat 9-month result

Close-up of market chart
Sinopharm Group (1099), a pharmaceutical company, rose around 5% after the company announced that 9-month net income grew 7.8% on year to 4.96 billion yuan on operating revenue of 327.61 billion yuan, up 4.8%.

Besides, Chinese Media reported that 4 Covid-19 Vaccines of Sinopharm are conducting the Phase III clinical tests in overseas countries.

Technically, the stock posted a rebound and broke above a declining channel. Currently, the prices stand above its 20-day moving average. The relative strength index also indicates a bullish divergence signal.

The bullish readers could set a support level at HK$16.40, while resistance levels would be HK$19.00 and HK$20.40.


Source: GAIN Capital, TradingView
Related tags: Equities Stocks China

Open an account in minutes

Experience award-winning platforms with fast and secure execution.

Web Trader platform

Our sophisticated web-based platform is packed with features.

Economic Calendar